Oskar Vilhelmsson Timmermand1, Thuy A Tran2, Sven-Erik Strand3, Johan Axelsson4. 1. Department of Medical Radiation Physics, Lund University, Lund, Sweden. 2. Lund University Bioimaging Center, Lund University, Lund, Sweden; and. 3. Department of Medical Radiation Physics, Lund University, Lund, Sweden Lund University Bioimaging Center, Lund University, Lund, Sweden; and. 4. Division of Atomic Physics, Department of Physics, Lund University, Lund, Sweden Johan.Axelsson@fysik.lth.se.
Abstract
UNLABELLED: In recent years, there has been increasing interest in noninvasive Cerenkov luminescence imaging (CLI) of in vivo radionuclide distribution in small animals, a method proven to be a high-throughput modality for confirmation of tracer uptake. 11B6 is an IgG1 monoclonal antibody that is specific to free human kallikrein-related peptidase 2, an antigen abundant in malignant prostatic tissue. Free human kallikrein-related peptidase 2 was targeted in prostate cancer xenografts using (177)Lu-labeled 11B6 in either murine or humanized forms for radionuclide therapy. In this setting, CLI was investigated as a tool for providing parameters of dosimetric importance during radionuclide therapy. First, longitudinal imaging of biokinetics using CLI and SPECT was compared. Second, the CLI signal was correlated to quantitative ex vivo tumor activity measurements. Finally, CLI was used to monitor the radionuclide treatment, and the integrated CLI radiance was found to correlate well with subject-specific tumor volume reduction. METHODS: 11B6 was radiolabeled with (177)Lu through the CHX-A″-DTPA chelator. In vivo CLI and SPECT imaging of (177)Lu-DTPA-11B6 uptake was performed on NMRI and BALB/c nude mice with subcutaneous LNCaP xenografts up to 14 d after injection. Tumor size was measured to assess response to radionuclide therapy. RESULTS: CLI correlated well with SPECT imaging and could be applied up to 14 d after injection of 20 MBq with the specific tracer used. Through integration of the CLI radiance as a function of time, a dose metric for the tumors could be formed that correlated exponentially with tumor volume reduction. CONCLUSION: CLI provided valuable intratherapeutic biokinetic measurements for treatment monitoring and could be used as a tool for subject-specific absorbed dose estimation.
UNLABELLED: In recent years, there has been increasing interest in noninvasive Cerenkov luminescence imaging (CLI) of in vivo radionuclide distribution in small animals, a method proven to be a high-throughput modality for confirmation of tracer uptake. 11B6 is an IgG1 monoclonal antibody that is specific to free humankallikrein-related peptidase 2, an antigen abundant in malignant prostatic tissue. Free humankallikrein-related peptidase 2 was targeted in prostate cancer xenografts using (177)Lu-labeled 11B6 in either murine or humanized forms for radionuclide therapy. In this setting, CLI was investigated as a tool for providing parameters of dosimetric importance during radionuclide therapy. First, longitudinal imaging of biokinetics using CLI and SPECT was compared. Second, the CLI signal was correlated to quantitative ex vivo tumor activity measurements. Finally, CLI was used to monitor the radionuclide treatment, and the integrated CLI radiance was found to correlate well with subject-specific tumor volume reduction. METHODS: 11B6 was radiolabeled with (177)Lu through the CHX-A″-DTPA chelator. In vivo CLI and SPECT imaging of (177)Lu-DTPA-11B6 uptake was performed on NMRI and BALB/c nude mice with subcutaneous LNCaP xenografts up to 14 d after injection. Tumor size was measured to assess response to radionuclide therapy. RESULTS: CLI correlated well with SPECT imaging and could be applied up to 14 d after injection of 20 MBq with the specific tracer used. Through integration of the CLI radiance as a function of time, a dose metric for the tumors could be formed that correlated exponentially with tumor volume reduction. CONCLUSION: CLI provided valuable intratherapeutic biokinetic measurements for treatment monitoring and could be used as a tool for subject-specific absorbed dose estimation.
Authors: Daniel L J Thorek; Philip A Watson; Sang-Gyu Lee; Anson T Ku; Stylianos Bournazos; Katharina Braun; Kwanghee Kim; Kjell Sjöström; Michael G Doran; Urpo Lamminmäki; Elmer Santos; Darren Veach; Mesruh Turkekul; Emily Casey; Jason S Lewis; Diane S Abou; Marise R H van Voss; Peter T Scardino; Sven-Erik Strand; Mary L Alpaugh; Howard I Scher; Hans Lilja; Steven M Larson; David Ulmert Journal: Sci Transl Med Date: 2016-11-30 Impact factor: 17.956
Authors: Florian C Maier; Julia Schmitt; Andreas Maurer; Walter Ehrlichmann; Gerald Reischl; Konstantin Nikolaou; Rupert Handgretinger; Bernd J Pichler; Wolfgang M Thaiss Journal: Oncotarget Date: 2016-10-11